Momenta

Investor Relations

NASDAQ: MNTA
Price
10.71
Change
+ 0.07
Day High
11.00
Day Low
10.51
Volume
538,500
4:00 PM ET on Aug 1, 2014
Stock price graph

Momenta Pharmaceuticals is a biotechnology company based in Cambridge, MA focused on the development of complex generics, follow-on biologics and novel drugs. In July 2010, the company's lead product (developed in collaboration with Sandoz) was approved as the first generic version of Lovenox® (enoxaparin sodium injection). The company’s development pipeline includes a generic version of Copaxone® (glatiramer acetate), also in collaboration with Sandoz, follow-on biologics in collaboration with Baxter, and necuparanib (formerly M402), a novel oncology drug candidate currently undergoing testing in early phase human clinical trials. Necuparanib has received Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) for the treatment of pancreatic cancer.

View Annual Report and Proxy Material

View all »   RSSRecent Releases

Jul 31, 2014
Momenta Pharmaceuticals Reports Second Quarter 2014 Financial Results

Jul 30, 2014
Momenta Pharmaceuticals to Webcast Presentation at the Canaccord Genuity Growth Conference

Last Revised 6/12/2012